Citadel Advisors
ANAB icon

Citadel Advisors’s AnaptysBio ANAB Stock Holding History

Citadel Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,400
Closed -$1.47M – 12912
2025
Q4 		$1.47M Buy
30,400
+23,400
+334% +$912K ﹤0.01% 6546
2025
Q3 		$214K Sell
7,000
-12,500
-64% -$287K ﹤0.01% 11123
2025
Q2 		$433K Buy
19,500
+8,600
+79% +$180K ﹤0.01% 8969
2025
Q1 		$203K Sell
10,900
-114,700
-91% -$1.91M ﹤0.01% 10419
2024
Q4 		$1.66M Buy
125,600
+97,600
+349% +$2.36M ﹤0.01% 6007
2024
Q3 		$938K Buy
28,000
+23,800
+567% +$813K ﹤0.01% 6994
2024
Q2 		$105K Buy
4,200
+2,000
+91% +$46.6K ﹤0.01% 10839
2024
Q1 		$49.5K Buy
2,200
+1,600
+267% +$37.9K ﹤0.01% 12178
2023
Q4 		$12.9K Sell
600
-3,900
-87% -$67.3K ﹤0.01% 12960
2023
Q3 		$80.8K Buy
+4,500
New +$85.9K ﹤0.01% 11165
2023
Q2 		– Sell
-300
Closed -$6.53K – 14286
2023
Q1 		$6.53K Sell
300
-1,600
-84% -$38.9K ﹤0.01% 13797
2022
Q4 		$58.9K Buy
+1,900
New +$53.7K ﹤0.01% 11931
2021
Q3 		– Sell
-8,300
Closed -$215K – 13745
2021
Q2 		$215K Sell
8,300
-24,200
-74% -$580K ﹤0.01% 12000
2021
Q1 		$700K Buy
+32,500
New +$820K ﹤0.01% 8944
2020
Q2 		– Sell
-11,000
Closed -$155K – 9716
2020
Q1 		$155K Sell
11,000
-84,900
-89% -$1.29M ﹤0.01% 8258
2019
Q4 		$1.56M Sell
95,900
-27,700
-22% -$655K ﹤0.01% 4818
2019
Q3 		$4.33M Buy
123,600
+101,900
+470% +$4.85M ﹤0.01% 3304
2019
Q2 		$1.22M Buy
21,700
+100
+0.5% +$7.2K ﹤0.01% 5371
2019
Q1 		$1.58M Buy
21,600
+3,600
+20% +$249K ﹤0.01% 4848
2018
Q4 		$1.15M Sell
18,000
-39,200
-69% -$2.92M ﹤0.01% 5098
2018
Q3 		$5.71M Buy
57,200
+36,400
+175% +$3.02M ﹤0.01% 2834
2018
Q2 		$1.48M Sell
20,800
-22,700
-52% -$1.9M ﹤0.01% 4566
2018
Q1 		$4.53M Buy
43,500
+40,300
+1,259% +$4.54M ﹤0.01% 2575
2017
Q4 		$322K Buy
+3,200
New +$236K ﹤0.01% 6347

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's ANAB Position: Q1 2026 in Review

Citadel Advisors increased its AnaptysBio (ANAB) stake by 113% in Q1 2026, buying an estimated $6.67M and bringing the position to 233,450 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Citadel Advisors first reported a position in ANAB in Q3 2017 and has held it in 32 quarters since. The position peaked at $64.8M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Citadel Advisors held 233,450 shares of AnaptysBio worth $12.9M as of Q1 2026.
  • Citadel Advisors bought 123,967 AnaptysBio shares in Q1 2026, an estimated $6.67M.
  • AnaptysBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2880 holding.
  • Citadel Advisors first reported a position in AnaptysBio in Q3 2017 and has held it in 32 quarters since.
  • Citadel Advisors's AnaptysBio position peaked at $64.8M in Q3 2018.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.